Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)

Yonsei University

Status and phase

Terminated

Phase 4

Conditions

Peripheral Artery Disease With Intermittent Claudication

Treatments

Drug: other anti-hypertensive drug

Drug: Olmesartan

Study type

Interventional

Funder types

Other

Identifiers

NCT02373462

4-2014-0888

Details and patient eligibility

About

To study the effect of olmesartan on walking distance and quality of life in peripheral artery disease patients with hypertension treated For intermittent claudication.

Enrollment

1 patient

Sex

All

Ages

20 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged between 20 and 85 years at visit 1
Patients with ankle-brachial index (ABI) of less than 0.9 in one or both legs with history of intermittent claudication stable for the previous 6 months
Patients whose statins, anti hypertensive medications and antiplatelet medications are stable for the past 6 months. Statins and cilostazol are allowed but needs to be stable for the past 6 months (diabetic medications may be changed)
Patients whose blood pressure is more than 140/90 mmHg with/without anti-hypertension treatment

Exclusion criteria

Blood pressure of more than 180/110 mmHg
Patients taking ARBs or ACE inhibitors treatment for at least 6 months before
Patients taking aldosterone receptor antagonists at least 6 months before
Patients with serum creatinine of more than 3 mg/dL
serum potassium (K+) > 5.5mg/dl
History of bilateral renal artery stenosis
History of acute coronary syndrome or heart failure hospitalization within 6 months
Peripheral arterial revascularization planned within 1 month
Critical limb ischemia
Patients with impaired cognition (e.g. dementia)
pregnancy or women at age of childbearing potential